株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

類鼻疽: パイプライン製品の分析

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 321927
出版日 ページ情報 英文 53 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.47円で換算しております。
Back to Top
類鼻疽: パイプライン製品の分析 Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2017
出版日: 2017年11月14日 ページ情報: 英文 53 Pages
概要

類鼻疽は、グラム陰性の好気性双極桿菌で土壌中に生息するバクテリアによっておこる感染症です。このバクテリアは吸入、摂取、傷口などから動物およびヒト双方に感染し、症状は発熱、咳、胸痛、頭痛、食欲不振などがあります。リスク要因には、肝疾患、糖尿病、サラセミア(地中海貧血)などがあります。

当レポートでは、類鼻疽に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

類鼻疽の概要

治療薬の開発

  • パイプライン製品:概要
  • 企業別のパイプライン
  • 大学/研究機関で開発されたパイプライン
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬の開発に従事している企業

  • Bavarian Nordic A/S
  • Emergent BioSolutions Inc
  • Grifols SA
  • Soligenix Inc
  • Syntiron LLC

薬剤のプロファイル

開発休止中のプロジェクト

製品開発のマイルストーン

  • 注目のニュースおよびプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9883IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2017, provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline landscape.

Burkholderia pseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open wounds. Signs and symptoms include fever, cough, chest pain, headache and anorexia. Risk factors include liver disease, diabetes, and thalassemia.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Burkholderia pseudomallei Infections (Melioidosis) - Overview 6
  • Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Development 7
  • Pipeline Overview 7
  • Pipeline by Companies 8
  • Pipeline by Universities/Institutes 9
  • Products under Development by Companies 10
  • Products under Development by Universities/Institutes 11
  • Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment 12
  • Assessment by Target 12
  • Assessment by Mechanism of Action 14
  • Assessment by Route of Administration 16
  • Assessment by Molecule Type 18
  • Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development 20
  • Bavarian Nordic A/S 20
  • Emergent BioSolutions Inc 20
  • Grifols SA 21
  • MerLion Pharmaceuticals Pte Ltd 21
  • Soligenix Inc 22
  • Syntiron LLC 22
  • Burkholderia pseudomallei Infections (Melioidosis) - Drug Profiles 24
  • ARD-3100 - Drug Profile 24
  • Product Description 24
  • Mechanism Of Action 24
  • R&D Progress 24
  • ARD-3150 - Drug Profile 28
  • Product Description 28
  • Mechanism Of Action 28
  • R&D Progress 28
  • Burkholderia pseudomallei vaccine - Drug Profile 35
  • Product Description 35
  • Mechanism Of Action 35
  • R&D Progress 35
  • Burkholderia vaccine - Drug Profile 36
  • Product Description 36
  • Mechanism Of Action 36
  • R&D Progress 36
  • EV-035 - Drug Profile 37
  • Product Description 37
  • Mechanism Of Action 37
  • R&D Progress 37
  • finafloxacin - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • GC-072 - Drug Profile 42
  • Product Description 42
  • Mechanism Of Action 42
  • R&D Progress 42
  • melioidosis vaccine - Drug Profile 43
  • Product Description 43
  • Mechanism Of Action 43
  • R&D Progress 43
  • SGX-943 - Drug Profile 44
  • Product Description 44
  • Mechanism Of Action 44
  • R&D Progress 44
  • Small Molecules for Infectious Diseases - Drug Profile 45
  • Product Description 45
  • Mechanism Of Action 45
  • R&D Progress 45
  • Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects 46
  • Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products 47
  • Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones 48
  • Featured News & Press Releases 48
  • Jun 28, 2017: MerLion and Dstl Awarded DTRA Grant to Explore the Use of Finafloxacin against Biological Threat Agents 48
  • May 31, 2016: FDA Grants Soligenix "Fast Track" Designation for SGX943 for the Treatment of Melioidosis 48
  • Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC 49
  • Aug 14, 2014: US DTRA to fund preclinical work on Evolva's antibiotic GC-072 49
  • Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development 50
  • Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis 50
  • Appendix 52
  • Methodology 52
  • Coverage 52
  • Secondary Research 52
  • Primary Research 52
  • Expert Panel Validation 52
  • Contact Us 52
  • Disclaimer 53

List of Tables

  • Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H2 2017 7
  • Number of Products under Development by Companies, H2 2017 8
  • Number of Products under Development by Universities/Institutes, H2 2017 9
  • Products under Development by Companies, H2 2017 10
  • Products under Development by Universities/Institutes, H2 2017 11
  • Number of Products by Stage and Target, H2 2017 13
  • Number of Products by Stage and Mechanism of Action, H2 2017 15
  • Number of Products by Stage and Route of Administration, H2 2017 17
  • Number of Products by Stage and Molecule Type, H2 2017 19
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Bavarian Nordic A/S, H2 2017 20
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Emergent BioSolutions Inc, H2 2017 21
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Grifols SA, H2 2017 21
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2017 22
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix Inc, H2 2017 22
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Syntiron LLC, H2 2017 23
  • Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, H2 2017 46
  • Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, H2 2017 47

List of Figures

  • Number of Products by Targets, H2 2017 12
  • Number of Products by Stage and Targets, H2 2017 12
  • Number of Products by Mechanism of Actions, H2 2017 14
  • Number of Products by Stage and Mechanism of Actions, H2 2017 14
  • Number of Products by Routes of Administration, H2 2017 16
  • Number of Products by Stage and Routes of Administration, H2 2017 16
  • Number of Products by Molecule Types, H2 2017 18
  • Number of Products by Stage and Molecule Type, H2 2017 18
Back to Top